Table 1. Plasma total cholesterol, plasma triglyceride, liver glutathione and liver superoxide dismutase activities at the end of the 3-week and 8-week studies.
| Control | Diabetic untreated | Diabetic with dapagliflozin | Diabetic with insulin | Diabetic with combination | ||
|---|---|---|---|---|---|---|
| Plasma total cholesterol (mg/dl) | 3-week | 67.0 ± 7.8 | 116.5 ± 34.3a) | 81.3 ± 16.7 | 81.5 ± 7.9 | 75.6 ± 4.0b) |
| 8-week | 60.8 ± 5.7 | 104.0 ± 13.5a) | 95.0 ± 25.3 | 62.0 ± 14.5b) | 58.0 ± 13.3b,c) | |
| Plasma triglyceride (mg/dl) | 3-week | 141.8 ± 32.5 | 643.3 ± 98.2a) | 569.7 ± 186.8a) | 278.5 ± 233.2b) | 151.3 ± 67.6b,c) |
| 8-week | 152.5 ± 31.8 | 453.0 ± 192.6 | 531.5 ± 196.4a) | 283.5 ± 162.5 | 92.5 ± 47.3b,c) | |
| Liver glutathione (nmol/mg protein) | 3-week | 15.8 ± 2.6 | 5.0 ± 1.4a) | 9.3 ± 2.1a) | 10.8 ± 1.9a,b) | 12.3 ± 1.9b) |
| 8-week | 24.3 ± 1.9 | 8.0 ± 2.2a) | 9.5 ± 5.9a) | 21.8 ± 4.6b,c) | 19.4 ± 4.8b,c) | |
| Liver superoxide dismutase activities (U/mg protein) | 3-week | 617.8 ± 130.9 | 386.3 ± 61.5a) | 337.3 ± 107.5a) | 326.8 ± 88.2a) | 370.3 ± 64.4b,c) |
| 8-week | 556.3 ± 85.3 | 389.5 ± 70.1 | 368.7 ± 69.1 | 642.8 ± 150.0b,c) | 706.3 ± 120.1b,c) |
The values are expressed as mean ± standard deviation. a) P<0.05 versus control group, b) P<0.05 versus diabetic untreated group, c) P<0.05 versus diabetic treated with dapagliflozin group.